Home » Stocks » Neos Therapeutics

Neos Therapeutics, Inc. (NEOS)

Stock Price: $0.735 USD 0.015 (2.10%)
Updated Aug 10, 2020 9:49 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 36.57M
Revenue (ttm) 64.51M
Net Income (ttm) -17.25M
Shares Out 49.75M
EPS (ttm) -0.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $0.735
Previous Close $0.720
Change ($) 0.015
Change (%) 2.10%
Day's Open 0.730
Day's Range 0.730 - 0.740
Day's Volume 81,348
52-Week Range 0.600 - 2.150

More Stats

Market Cap 36.57M
Enterprise Value 62.02M
Earnings Date (est) Aug 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 49.75M
Float 37.41M
EPS (basic) -0.35
EPS (diluted) -0.35
FCF / Share -0.14
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.18M
Short Ratio 6.65
Short % of Float 2.37%
Beta 1.25
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 0.57
PB Ratio n/a
Revenue 64.51M
Operating Income -10.48M
Net Income -17.25M
Free Cash Flow -6.76M
Net Cash -25.45M
Net Cash / Share -0.51
Gross Margin 61.27%
Operating Margin -16.25%
Profit Margin -26.70%
FCF Margin -10.48%
ROA -6.85%
ROE -1,971.08%
ROIC -21.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$7.00*
(852.25% upside)
Low
2.00
Current: $0.735
High
10.00
Target: 7.00
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue64.6549.9927.1310.033.790.761.04
Revenue Growth29.33%84.24%170.43%164.58%400.26%-27.39%-
Gross Profit39.5323.0613.10-1.70-2.14-2.63-1.49
Operating Income-10.42-43.50-56.54-75.82-26.58-18.47-17.09
Net Income-16.90-51.68-65.77-82.75-30.78-20.85-15.63
Shares Outstanding49.7232.2924.7516.057.580.880.79
Earnings Per Share-0.34-1.60-2.66-5.16-4.38-27.56-28.45
Operating Cash Flow-10.78-41.44-53.26-70.65-25.87-17.39-14.96
Capital Expenditures-1.09-1.36-2.50-3.55-1.02-0.34-2.02
Free Cash Flow-11.87-42.80-55.76-74.20-26.89-17.73-16.97
Cash & Equivalents24.8946.4850.4239.7890.7616.340.00
Total Debt48.8751.7759.8363.5234.2424.77-
Net Cash / Debt-23.98-5.30-9.42-23.7456.52-8.430.00
Assets90.8711110480.1412345.23-
Liabilities97.0010495.1681.6944.14124-
Book Value-6.137.858.95-1.5578.37-78.78-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Neos Therapeutics, Inc.
Country United States
Employees 213
CEO Gerald W. McLaughlin

Stock Information

Ticker Symbol NEOS
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: NEOS
IPO Date July 23, 2015

Description

Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate for treating of ADHD; Adzenys ER amphetamine to treat ADHD; and generic Tussionex hydrocodone and chlorpheniramine for cough and upper respiratory symptoms of a cold. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas.